A 17-year-old man with chronic long-standing AA was enrolled in a clinical trial examining the efficacy of baricitinib for a proposed IFN mediated autoinflammatory syndrome, CANDLE syndrome (NCT01724580). The gene discussed is IFNA1; the disease is proteosome-associated autoinflammatory syndrome.